2.02
+0.03(+1.51%)
Currency In USD
| Previous Close | 1.99 |
| Open | 1.99 |
| Day High | 2.26 |
| Day Low | 1.78 |
| 52-Week High | 40.8 |
| 52-Week Low | 1.78 |
| Volume | 5.11M |
| Average Volume | 68,152 |
| Market Cap | 916,137 |
| PE | 0 |
| EPS | 657.48 |
| Moving Average 50 Days | 3.27 |
| Moving Average 200 Days | 5.95 |
| Change | 0.03 |
If you invested $1000 in Bluejay Diagnostics, Inc. (BJDX) since IPO date, it would be worth $0.05 as of February 21, 2026 at a share price of $2.02. Whereas If you bought $1000 worth of Bluejay Diagnostics, Inc. (BJDX) shares 3 years ago, it would be worth $0.34 as of February 21, 2026 at a share price of $2.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised
GlobeNewswire Inc.
Yesterday at 11:30 AM GMT
ACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement have been fully exercised, an
Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026
GlobeNewswire Inc.
Feb 17, 2026 11:30 AM GMT
ACTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that it has successfully enrolled 545 patients in its SYMON™ II multicenter clinical study and has made substantial progress in advancing manufacturi
Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
GlobeNewswire Inc.
Jan 27, 2026 1:00 PM GMT
ACTON, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care s